Cancer immunotherapy and its facilitation by nanomedicine
Abstract Cancer immunotherapy has sparked a wave of cancer research, driven by recent successful proof-of-concept clinical trials. However, barriers are emerging during its rapid development, including broad adverse effects, a lack of reliable biomarkers, tumor relapses, and drug resistance. Integra...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2024-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b66c4380d8b14d55b7be0aac7c7188db | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Chao Sui |e author |
| 700 | 1 | 0 | |a Heqing Wu |e author |
| 700 | 1 | 0 | |a Xinxin Li |e author |
| 700 | 1 | 0 | |a Yuhang Wang |e author |
| 700 | 1 | 0 | |a Jiaqi Wei |e author |
| 700 | 1 | 0 | |a Jianhua Yu |e author |
| 700 | 1 | 0 | |a Xiaojin Wu |e author |
| 245 | 0 | 0 | |a Cancer immunotherapy and its facilitation by nanomedicine |
| 260 | |b BMC, |c 2024-08-01T00:00:00Z. | ||
| 500 | |a 10.1186/s40364-024-00625-6 | ||
| 500 | |a 2050-7771 | ||
| 520 | |a Abstract Cancer immunotherapy has sparked a wave of cancer research, driven by recent successful proof-of-concept clinical trials. However, barriers are emerging during its rapid development, including broad adverse effects, a lack of reliable biomarkers, tumor relapses, and drug resistance. Integration of nanomedicine may ameliorate current cancer immunotherapy. Ultra-large surface-to-volume ratio, extremely small size, and easy modification surface of nanoparticles enable them to selectively detect cells and kill cancer cells in vivo. Exciting synergistic applications of the two approaches have emerged in treating various cancers at the intersection of cancer immunotherapy and cancer nanomedicine, indicating the potential that the combination of these two therapeutic modalities can lead to new paradigms in the treatment of cancer. This review discusses the status of current immunotherapy and explores the possible opportunities that the nanomedicine platform can make cancer immunotherapy more powerful and precise by synergizing the two approaches. | ||
| 546 | |a EN | ||
| 690 | |a Cancer | ||
| 690 | |a Immunotherapy | ||
| 690 | |a Nanomedicine | ||
| 690 | |a Nanotechnology | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Biomarker Research, Vol 12, Iss 1, Pp 1-29 (2024) | |
| 787 | 0 | |n https://doi.org/10.1186/s40364-024-00625-6 | |
| 787 | 0 | |n https://doaj.org/toc/2050-7771 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b66c4380d8b14d55b7be0aac7c7188db |z Connect to this object online. |